PERSEPHONEEstudio clínico para adultos con enfermedad pulmonar obstructiva crónica eosinofílica

Lunsekimig

Lunsekimig

Placebo

Annualized rate of moderate-to-severe chronic obstructive pulmonary disease (COPD) exacerbations

Annualized rate of severe COPD exacerbations

Change from baseline in pre-Bronchodilator Forced Expiratory Volume in 1 second (pre-BD FEV1)

Change from baseline in the SGRQ-C total score

SGRQ responder defined as an improvement of ≥4 points in the SGRQ-C total score

Change from baseline in the Chronic airways assessment Test (CAAT) score

Change from baseline in the E-RS:COPD total score

Time to first moderate or severe COPD exacerbation

Time to first severe COPD exacerbation

Incidence of participants with TEAEs, including AESIs, and SAEs

Incidence of potentially clinically significant laboratory abnormalities

Incidence and titer of antidrug antibodies (ADAs)

Change from baseline in post-Bronchodilator Forced Expiratory Volume in 1 second (post-BD FEV1)

CAAT responder defined as an improvement of ≥2 points in the CAAT total score

E-RS:COPD responder defined as an improvement of ≥2 points in the E-RS:COPD total score

Serum concentration of lunsekimig